RecruitingDrug trialStudy of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck CancerThis is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.